<DOC>
	<DOCNO>NCT02866903</DOCNO>
	<brief_summary>Peritoneal carcinosis ( PC ) correspond locoregional extension peritoneum rare primary peritoneal cancer , frequently distant extension digestive cancer ( colorectal gastric ) gynecological ( ovarian , fallopian tube , endometrial ) . PC consider distinct oncological entity genesis , natural history , response systematic treatment differ metastasis . The development PC , observe 25-35 % colorectal cancer , generally consider unfavorable event course disease . The prognosis define possibility complete resection , possibly neoadjuvant treatment . The benefit provide combination cytoreductive surgery heat intraperitoneal chemotherapy ( HIPEC ) respect systemic chemotherapy patient PC colorectal origin demonstrate base overall survival several randomize trial , among one evaluate oxaliplatin . The evaluation clinical benefit-risk relate repeated administration non-hyperthermic intraperitoneal chemotherapy , validated ovarian cancer , patient PC colorectal origin already investigate several international team . The FOLFOXIRI + bevacizumab every 2 week modern therapeutic option patient disease . The intraperitoneal rather intravenous ( IV ) administration oxaliplatin , combination , could increase response peritoneal lesion know relatively insensitive IV chemotherapy .</brief_summary>
	<brief_title>Safety Intraperitoneal ( IP ) OXAliplatin ( OXA ) Association With Systemic FOLFIRI Bevacizumab Chemotherapy Patients With Peritoneal Carcinosis</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>≥18 year old ≤ 75 year old ECOG Performance Status ( PS ) 02 Peritoneal carcinosis locoregional extension metastasis colorectal origin uncertain resectability PCI &gt; 20 / infiltration hepatic pedicle / necessary digestive tract resection Systemic chemotherapy indication , compatible FOLFIRI + bevacizumab combination Satisfactory haematological evaluation : PNN rate great 1500 / mm3 , platelet count great 100 G / l ; Satisfactory renal hepatic function : serum creatinine ≤1.5 time normal low value creatinine clearance ≥50 ml / min , bilirubin ≤1.25 time low normal value , AST / ALT ≤1.5 time low normal value ( ≤5 time low normal value patient liver metastasis ) No unstable condition : myocardial infarction within 6 month prior start study , congestive heart failure , unstable angina , active cardiomyopathy , unstable rhythm disorder , uncontrolled hypertension , uncontrolled psychiatric disorder , severe infection , peptic ulcer condition could aggravate treatment limit compliance ( investigator assessment ) ; No limitation number previous treatment ; Patients may receive conventional cytotoxic chemotherapy , hormonal immunological target biological agent . They recover previous grade ≤2 toxicity Written inform consent Known RAS status . Extraperitoneal metastases site number preclude potentially curative surgery moment course disease Sign bowel obstruction lesion whose topography indicate risk intestinal perforation inflammatory bowel disease ECOG PS 34 Contraindication placement intraperitoneal central line Contraindication specifically related intraperitoneal administration oxaliplatin known history hypersensitivity oxaliplatin excipients peripheral sensory neuropathy grade ≥2 Pregnant lactate woman Unable give consent Patient legal protection measure Refusal participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Peritoneal carcinosis</keyword>
	<keyword>intraperitoneal ( IP ) OXAliplatin</keyword>
	<keyword>Phase I/II dose escalation trial</keyword>
	<keyword>FOLFIRI Bevacizumab chemotherapy</keyword>
</DOC>